[go: up one dir, main page]

DK2625174T3 - Co-krystaller og salte af ccr3-inhibitorer - Google Patents

Co-krystaller og salte af ccr3-inhibitorer Download PDF

Info

Publication number
DK2625174T3
DK2625174T3 DK11764572.1T DK11764572T DK2625174T3 DK 2625174 T3 DK2625174 T3 DK 2625174T3 DK 11764572 T DK11764572 T DK 11764572T DK 2625174 T3 DK2625174 T3 DK 2625174T3
Authority
DK
Denmark
Prior art keywords
crystals
salts
ccr3 inhibitors
ccr3
inhibitors
Prior art date
Application number
DK11764572.1T
Other languages
English (en)
Inventor
Markus Frank
Hans Haeberle
Manuel Henry
Thorsten Pachur
Marco Santagostino
Uwe Stertz
Thomas Trebing
Ulrike Werthmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK2625174T3 publication Critical patent/DK2625174T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11764572.1T 2010-10-07 2011-10-06 Co-krystaller og salte af ccr3-inhibitorer DK2625174T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
DK2625174T3 true DK2625174T3 (da) 2015-02-02

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11764572.1T DK2625174T3 (da) 2010-10-07 2011-10-06 Co-krystaller og salte af ccr3-inhibitorer

Country Status (37)

Country Link
US (3) US8742115B2 (da)
EP (1) EP2625174B1 (da)
JP (1) JP5794713B2 (da)
KR (3) KR102163874B1 (da)
CN (1) CN103140486B (da)
AP (1) AP3268A (da)
AR (1) AR083353A1 (da)
AU (1) AU2011311530B2 (da)
BR (2) BR112013008211B1 (da)
CA (1) CA2807255C (da)
CL (1) CL2013000488A1 (da)
CO (1) CO6710910A2 (da)
CY (1) CY1116168T1 (da)
DK (1) DK2625174T3 (da)
EA (1) EA029097B1 (da)
EC (1) ECSP13012600A (da)
ES (1) ES2535264T3 (da)
GE (1) GEP20166488B (da)
HR (1) HRP20150419T1 (da)
HU (1) HUE024540T2 (da)
IL (1) IL224269A (da)
MA (1) MA34545B1 (da)
ME (1) ME02040B (da)
MX (1) MX2013003785A (da)
MY (1) MY167898A (da)
NZ (1) NZ605827A (da)
PE (1) PE20140188A1 (da)
PH (1) PH12013500644A1 (da)
PL (1) PL2625174T3 (da)
PT (1) PT2625174E (da)
RS (1) RS53858B1 (da)
SG (1) SG188949A1 (da)
SI (1) SI2625174T1 (da)
TW (1) TWI546294B (da)
UA (1) UA109290C2 (da)
UY (1) UY33655A (da)
WO (1) WO2012045803A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
AU2018248425B2 (en) * 2017-04-05 2024-03-28 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
EP3606525B1 (en) * 2017-04-05 2025-12-10 Alkahest, Inc. Compositions for treating aging-associated impairments using ccr3-inhibitors
CN111343983A (zh) * 2017-10-13 2020-06-26 万能溶剂有限公司 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
SG11202102105VA (en) * 2018-09-26 2021-04-29 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EP4164643A4 (en) * 2020-06-11 2024-07-03 Alkahest, Inc. METHODS OF IMPROVING THE OUTCOME OF RETINAL-ASSOCIATED DISEASE USING CCR3 INHIBITORS
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
EP1448528A2 (en) * 2001-11-29 2004-08-25 Schering Corporation Preparation of pharmaceutical salts of 4((z)-(4-bromophenyl)(ethoxyimino)methyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-4'-methyl-1,4'bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
CA2514092C (en) 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
WO2005040129A2 (en) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Ccr3 receptor antagonists
US7705153B2 (en) 2004-02-05 2010-04-27 Schering Corporation Bipiperdine derivatives useful as CCR3 antagonists
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
JP2009533416A (ja) * 2006-04-12 2009-09-17 ファイザー・リミテッド ケモカインccr5受容体の調節剤としてのピロリジン誘導体
RU2439065C2 (ru) 2006-04-20 2012-01-10 Ф.Хоффманн-Ля Рош Аг Производные диазепана в качестве модуляторов хемокиновых рецепторов
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
EA201300436A8 (ru) 2018-01-31
RS53858B1 (sr) 2015-08-31
HUE024540T2 (hu) 2016-01-28
CY1116168T1 (el) 2017-02-08
KR20130118313A (ko) 2013-10-29
KR101844215B1 (ko) 2018-04-03
US9233950B2 (en) 2016-01-12
PE20140188A1 (es) 2014-02-26
CO6710910A2 (es) 2013-07-15
ME02040B (me) 2015-05-20
TW201305134A (zh) 2013-02-01
CN103140486A (zh) 2013-06-05
HRP20150419T1 (hr) 2015-05-22
NZ605827A (en) 2015-09-25
JP2013542207A (ja) 2013-11-21
BR112013008211A8 (pt) 2017-10-10
CA2807255A1 (en) 2012-04-12
EA029097B1 (ru) 2018-02-28
EA201300436A1 (ru) 2013-08-30
IL224269A (en) 2017-08-31
CL2013000488A1 (es) 2013-07-05
BR112013008211B1 (pt) 2021-08-24
AR083353A1 (es) 2013-02-21
PT2625174E (pt) 2015-03-09
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
CA2807255C (en) 2018-11-13
MA34545B1 (fr) 2013-09-02
US20120264729A1 (en) 2012-10-18
PH12013500644A1 (en) 2013-05-20
US20150105371A1 (en) 2015-04-16
GEP20166488B (en) 2016-06-10
UA109290C2 (uk) 2015-08-10
EP2625174B1 (en) 2015-01-21
US8742115B2 (en) 2014-06-03
JP5794713B2 (ja) 2015-10-14
PL2625174T3 (pl) 2015-06-30
WO2012045803A1 (en) 2012-04-12
ECSP13012600A (es) 2013-07-31
AP3268A (en) 2015-05-31
AU2011311530A1 (en) 2013-01-31
SG188949A1 (en) 2013-05-31
AU2011311530B2 (en) 2015-04-09
TWI546294B (zh) 2016-08-21
EP2625174A1 (en) 2013-08-14
BR122021010665B1 (pt) 2022-03-15
BR112013008211A2 (pt) 2016-06-21
MX2013003785A (es) 2013-06-05
KR20190104645A (ko) 2019-09-10
MY167898A (en) 2018-09-26
US20140135307A1 (en) 2014-05-15
UY33655A (es) 2012-04-30
AP2013006679A0 (en) 2013-01-31
ES2535264T3 (es) 2015-05-07
SI2625174T1 (sl) 2015-03-31
CN103140486B (zh) 2016-08-03
KR102239690B1 (ko) 2021-04-13

Similar Documents

Publication Publication Date Title
DK2625174T3 (da) Co-krystaller og salte af ccr3-inhibitorer
DK2782570T3 (da) Heterocykliske hæmmere af glutaminase
DK2598483T3 (da) Ampk-aktiverende heterocykliske forbindelser og fremgangsmåder til anvendelse af disse
DK3202460T3 (da) Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme
DK2794907T4 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
DK3012329T3 (da) Fremgangsmåder og materialer til at vurdere tab af heterozygositet
DK2694091T3 (da) Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DK3357511T3 (da) Inhibitorer af t-celleaktivering
DK2807926T3 (da) Salte og polymorfer af en tetracyclinforbindelse
DK3656765T3 (da) Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK2583586T3 (da) Indretning til registrering af kollisioner og tilsvarende fremgangsmåde
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
DK2563531T3 (da) Fremgangsmåde og indretning til fordøjelse af væv
DK2700234T3 (da) Fremgangsmåde og indretning til komprimeret kodning med tab af data
DK3078743T3 (da) Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
DK2318396T3 (da) Krystalform af posaconazol
DK2638149T3 (da) Immortalisering af epitelceller og fremgangsmåder til anvendelse
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
DK3125131T3 (da) System og fremgangsmåde til cache-lagring af information
DK2658551T3 (da) Behandling af erektil dysfunktion og andre indikationer